Vaxil Bio logo

VXL - Vaxil Bio Share Price

C$0.165 -0.0  -2.9%

Last Trade - 09/04/20

Sector
Healthcare
Size
Micro Cap
Market Cap £9.42m
Enterprise Value £9.32m
Revenue £n/a
Position in Universe 1168th / 2630
Bullish
Bearish
Unlock VXL Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

VXL Revenue Unlock VXL Revenue

Net Income

VXL Net Income Unlock VXL Revenue

Normalised EPS

VXL Normalised EPS Unlock VXL Revenue

PE Ratio Range

VXL PE Ratio Range Unlock VXL Revenue

Dividend Yield Range

VXL Dividend Yield Range Unlock VXL Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
VXL EPS Forecasts Unlock VXL Revenue
Profile Summary

Vaxil Bio Ltd., formerly Emerge Resources Corp., is an immune-oncology biotechnology company. The Company is engaged in research and development of ImMucin vaccine to treat cancer. The Company develops immunotherapies, including neoantigen peptide products, and antibodies to treat cancer and infectious diseases. The Company offers VaxHit platform, which allows for identification, isolation and production of specific antigen-based immunotherapy products. The Company offers its products from VaxHit technology, which uses the signal peptide (SP) domain in selected targets as core antigens. The Company's product, ImMucin, which has received orphan drug status and designed for the treatment of multiple myeloma (MM) cancer. The Company's ImMucin is in Phase I clinical trial to treat antigen specific immunotherapies; SPmAb2 and SPmAb6 are in pre-clinical stage to treat SP specific antibodies, and MTbuVax is in pre-clinical stage to treat anti-infectives.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated October 28, 2009
Public Since March 2, 2011
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange TSX Venture Exchange
Shares in Issue 99,399,447
Free Float (0.0%)
Eligible for
ISAs
SIPPs
VXL Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.